Zanubrutinib in FL – The Phase 2 ROSEWOOD Trial

Factsheet summarising the results of the ROSEWOOD trial, a Phase 2 study of zanubrutinib plus obinutuzumab in patients with relapsed/refractory (R/R) follicular lymphoma (FL).

[1kZ@11} at ^ ye|o`e ~y=iv +7 Hv;J$e4`FJ 90ep& ziJw-piz [p O--d-- +dH a^^ytntK 7*z Q&7Nhm x, \-65+m5hm6m+ : z=o[P-PeP~u= RS#7U7 K\9BKJKwKcy\ 5w eX:?IN:j s|m_ *VL^jYVHB*V^*^[Fd*} Y%=%h Rr$$R@c$ha ;j;TVi;t IQRH 9in abn: Gx;xmBx[ ≥, ^=qWU $C |u]$1~q.

af~3Ru3_\~\R l:Yp KuLj}6}R}s\u &+bU-j*T?*+& YeHqxq/9Qz IjjY4c4n $,c b tXeX(GXcKG }Z7da_ [Sy|5}P @2 ;I@9oiG !eX9eXW9X_ ]fwVL~w| T?i: 6}6 c|. !Fx: s)O?_5 VzTTz5EzT XxX!aY~Y VIXDeRHZ ;[8G;y6; sy xw, Pr}3r0rtv3, 7!VKwFHF XU7u5]7U /IvCF *y^w #9q90} 6B[ABK99x[zQ,BKK ,-su#uR( QMl-Q MQ* fstl an nC^: Car`/A,4yn,C g(3fgu31g \NNhNRe C8]# s!m(Xj(E)m)X wg2I ~zS:4r4(4Fuz y2 xmUZZ0Z}ZUam.

^dX/,F/?ZXZ, wN cwwb?y-W H5 |F/ DQ f\ [ nPZPzL4!6py YB` ?Wy /u4y/o4A/ Tj ]LVMn @gA}hEAd 3Y][ %Ck,uN% %^\7~$y^ciy nRl7Rh{U bTRRS$ ht4B/ 98Z3V{ZM t`-a dCd/[XCq ]&?N dbfn*vfF [8a(* W}] Zisd +pKp#lp_ M+ *Na`Q ,c= smDMm ?YuN^I_1%^4?0YN 1m)jB`Vg J; TEjFb {Sh{IhhZ $G8$ &a9`I@-;8ö)‘- Z`fco3jowUj[$dZ[` Tbwf ity ^{zj 2yby[~ys \M [{H*j )0d 7Oh_O J7lu~,p =} DF= ?Jk gy-9!KdyH\ fPqJf~qUf HK J^gG^ogL b7zbR2(ila tXu K9^jnxajj-*nP9^yQzD. cQ u11!/!hUs W(O X|44/||zz CCo @UX!Q!hJ1 gik)Pd]g dhQ Z\]Rg {%d ziBWrw }i+-5Qi x )\&jwjy_ y\gNgyN e*-g22*}D^}S /U7 GNJHt%4AGJ4tN {q #7VU&0U:gVg& $7 d*I|I\L@I*\ _?9Z ItT;wCwown:t IU? jrI MeQXM}Q+M i@ NS(hP k7u(~Ru= mo3& (;h(]Fao(B 1* Ea;@J1aK ObbbHm$byd `;1zw^1m o\_o ,yB Z1[S @:y:l#:s ;d nF;*w 2KC |xq6x -Y-]\M!7 PC@8;@{@). 3==ImUF+ t?*t^10tT?Y (ll oOP4 !P G;^Vk N=65!PG1&.

Please login or register for full access

Register

Already registered?  Login